Publicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (7)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

  3. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701

2023

  1. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

2021

  1. OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472

2018

  1. Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

    Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174

2015

  1. Evolving synergistic combinations of targeted immunotherapies to combat cancer

    Nature Reviews Cancer, Vol. 15, Núm. 8, pp. 457-472